Search Results - "PATTERSON, Christopher J. J"

Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia by Treon, Steven P, Tripsas, Christina K, Meid, Kirsten, Warren, Diane, Varma, Gaurav, Green, Rebecca, Argyropoulos, Kimon V, Yang, Guang, Cao, Yang, Xu, Lian, Patterson, Christopher J, Rodig, Scott, Zehnder, James L, Aster, Jon C, Harris, Nancy Lee, Kanan, Sandra, Ghobrial, Irene, Castillo, Jorge J, Laubach, Jacob P, Hunter, Zachary R, Salman, Zeena, Li, Jianling, Cheng, Mei, Clow, Fong, Graef, Thorsten, Palomba, M. Lia, Advani, Ranjana H

“…In a study conducted at three institutions, ibrutinib was associated with major responses in 73% of patients with Waldenström's macroglobulinemia who had…”
Get full text

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia by Treon, Steven P, Xu, Lian, Yang, Guang, Zhou, Yangsheng, Liu, Xia, Cao, Yang, Sheehy, Patricia, Manning, Robert J, Patterson, Christopher J, Tripsas, Christina, Arcaini, Luca, Pinkus, Geraldine S, Rodig, Scott J, Sohani, Aliyah R, Harris, Nancy Lee, Laramie, Jason M, Skifter, Donald A, Lincoln, Stephen E, Hunter, Zachary R

“…Waldenström's macroglobulinemia is a lymphoplasmacytic lymphoma. Genetic analysis has revealed a common mutation (L265P) in MYD88 in more than 90% of patients…”
Get full text

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies by Treon, Steven P, Xu, Lian, Guerrera, Maria Luisa, Jimenez, Cristina, Hunter, Zachary R, Liu, Xia, Demos, Maria, Gustine, Joshua, Chan, Gloria, Munshi, Manit, Tsakmaklis, Nicholas, Chen, Jiaji G, Kofides, Amanda, Sklavenitis-Pistofidis, Romanos, Bustoros, Mark, Keezer, Andrew, Meid, Kirsten, Patterson, Christopher J, Sacco, Antonio, Roccaro, Aldo, Branagan, Andrew R, Yang, Guang, Ghobrial, Irene M, Castillo, Jorge J

“…Next-generation sequencing has revealed recurring somatic mutations in Waldenström macroglobulinemia (WM), including (95%-97%), (30%-40%), (17%), and (8%-15%)…”
Get full text

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia by Yang, Guang, Zhou, Yangsheng, Liu, Xia, Xu, Lian, Cao, Yang, Manning, Robert J., Patterson, Christopher J., Buhrlage, Sara J., Gray, Nathanael, Tai, Yu-Tzu, Anderson, Kenneth C., Hunter, Zachary R., Treon, Steven P.

“…Myeloid differentiation factor 88 (MYD88) L265P somatic mutation is highly prevalent in Waldenström macroglobulinemia (WM) and supports malignant growth…”
Get full text

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia by Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M., Buske, Christian, Castillo, Jorge J., García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C., Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J., Treon, Steven P., Dimopoulos, Meletios A.

“…Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of…”
Get full text

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction by Xu, Lian, Hunter, Zachary R., Yang, Guang, Zhou, Yangsheng, Cao, Yang, Liu, Xia, Morra, Enrica, Trojani, Alessandra, Greco, Antonino, Arcaini, Luca, Varettoni, Marzia, Brown, Jennifer R., Tai, Yu-Tzu, Anderson, Kenneth C., Munshi, Nikhil C., Patterson, Christopher J., Manning, Robert J., Tripsas, Christina K., Lindeman, Neal I., Treon, Steven P.

“…By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in…”
Get full text

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 by TREON, Steven P, LOAKIMIDIS, Leukothea, KEOGH, George P, MYERS, Thomas J, BORAL, Andy, BIRNER, Ann, ESSELTINE, Dixie L, GHOBRIAL, Irene M, SOUMERAI, Jacob D, PATTERSON, Christopher J. J, SHEEHY, Patricia, NELSON, Marybeth, WILLEN, Michael, MATOUS, Jeffrey, MATTERN, John, DIENER, Jakow G

“…We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM). A cycle…”
Get full text

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib by Yang, Guang, Buhrlage, Sara J., Tan, Li, Liu, Xia, Chen, Jie, Xu, Lian, Tsakmaklis, Nicholas, Chen, Jiaji G., Patterson, Christopher J., Brown, Jennifer R., Castillo, Jorge J., Zhang, Wei, Zhang, Xiaofeng, Liu, Shuai, Cohen, Philip, Hunter, Zachary R., Gray, Nathanael, Treon, Steven P.

“…Activating mutations in MYD88 are present in ∼95% of patients with Waldenström macroglobulinemia (WM), as well as other B-cell malignancies including activated…”
Get full text

MYD88 wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival by Treon, Steven P., Gustine, Joshua, Xu, Lian, Manning, Robert J., Tsakmaklis, Nicholas, Demos, Maria, Meid, Kirsten, Guerrera, Maria L., Munshi, Manit, Chan, Gloria, Chen, Jiaji, Kofides, Amanda, Patterson, Christopher J., Yang, Guang, Liu, Xia, Severns, Patricia, Dubeau, Toni, Hunter, Zachary R., Castillo, Jorge J.

“…Summary MYD88 mutations are present in 95% of Waldenstrom Macroglobulinaemia (WM) patients, and support diagnostic discrimination from other IgM‐secreting…”
Get full text

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy by Gustine, Joshua N, Sarosiek, Shayna, Flynn, Catherine A, Meid, Kirsten, Leventoff, Carly, White, Timothy, Guerrera, Maria Luisa, Xu, Lian, Kofides, Amanda, Tsakmaklis, Nicholas, Munshi, Manit, Demos, Maria, Patterson, Christopher J, Liu, Xia, Yang, Guang, Hunter, Zachary R, Branagan, Andrew R, Treon, Steven P, Castillo, Jorge J

“…Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with…”
Get full text

MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4 by Guerrera, Maria Luisa, Tsakmaklis, Nickolas, Xu, Lian, Yang, Guang, Demos, Maria, Kofides, Amanda, Chan, Gloria G, Manning, Robert J, Liu, Xia, Chen, Jiaji G, Munshi, Manit, Patterson, Christopher J, Castillo, Jorge J, Dubeau, Toni, Gustine, Joshua, Carrasco, Ruben D, Arcaini, Luca, Varettoni, Marzia, Cazzola, Mario, Treon, Steven P, Hunter, Zachary R

Get full text

Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs by LELEU, Xavier, SOUMERAI, Jacob, MOREAU, Anne-Sophie, PATTERSON, Christopher J, GHOBRIAL, Irene M, TREON, Steven P, ROCCARO, Aldo, HATJIHARISSI, Evdoxia, HUNTER, Zachary R, MANNING, Robert, CICCARELLI, Bryan T, SACCO, Antonio, IOAKIMIDIS, Leukothea, ADAMIA, Sophia

“…Nucleoside analogs (NAs) are considered as appropriate agents in the treatment of Waldenström macroglobulinemia (WM), a lymphoplasmacytic lymphoma. Sporadic…”
Get full text

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib by Vos, Josephine M, Tsakmaklis, Nickolas, Patterson, Christopher J, Meid, Kirsten, Castillo, Jorge J, Brodsky, Philip, Ganz, Tomas, Pals, Steven T, Kersten, Marie José, Xu, Lian, Yang, Guang, Treon, Steven P, Hunter, Zachary R

Get full text

Thalidomide and rituximab in Waldenstrom macroglobulinemia by Treon, Steven P., Soumerai, Jacob D., Branagan, Andrew R., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Briccetti, Frederick M., Pasmantier, Mark, Zimbler, Harvey, Cooper, Robert B., Moore, Maria, Hill, John, Rauch, Alan, Garbo, Lawrence, Chu, Luis, Chua, Cynthia, Nantel, Stephen H., Lovett, David R., Boedeker, Hans, Sonneborn, Henry, Howard, John, Musto, Paul, Ciccarelli, Bryan T., Hatjiharissi, Evdoxia, Anderson, Kenneth C.

“…Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab…”
Get full text

Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia by Treon, Steven P, Soumerai, Jacob D, Branagan, Andrew R, Hunter, Zachary R, Patterson, Christopher J, Ioakimidis, Leukothea, Chu, Luis, Musto, Paul, Baron, Ari D, Nunnink, Johannes C, Kash, Joseph J, Terjanian, Terenig O, Hyman, Paul M, Nawfel, Elena L, Sharon, David J, Munshi, Nikhil C, Anderson, Kenneth C

“…Purpose: Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We…”
Get full text

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas by Liu, Xia, Chen, Jiaji G., Munshi, Manit, Hunter, Zachary R., Xu, Lian, Kofides, Amanda, Tsakmaklis, Nickolas, Demos, Maria G., Guerrera, Maria Luisa, Chan, Gloria G., Jimenez, Cristina, Patterson, Christopher J., Meid, Kirsten, Keezer, Andrew, Castillo, Jorge J., Treon, Steven P., Yang, Guang

“…Hematopoietic cell kinase (HCK) is an SRC family member that is aberrantly upregulated in B-cell neoplasms dependent on MYD88-activating mutations and supports…”
Get full text

CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia by Ho, Allen W., Hatjiharissi, Evdoxia, Ciccarelli, Bryan T., Branagan, Andrew R., Hunter, Zachary R., Leleu, Xavier, Tournilhac, Olivier, Xu, Lian, O'Connor, Kelly, Manning, Robert J., Santos, Daniel Ditzel, Chemaly, Mariana, Patterson, Christopher J., Soumerai, Jacob D., Munshi, Nikhil C., McEarchern, Julie A., Law, Che-Leung, Grewal, Iqbal S., Treon, Steven P.

“…Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by an IgM monoclonal gammopathy and bone marrow (BM) infiltration with…”
Get full text

Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials by Castillo, Jorge J., Gustine, Joshua N., Meid, Kirsten, Flynn, Catherine A., Demos, Maria G., Guerrera, Maria L., Jimenez, Cristina, Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Xu, Lian, Yang, Guang, Hunter, Zachary R., Treon, Steven P.

“…Ibrutinib is the first approved therapy for symptomatic patients with Waldenström macroglobulinemia (WM). The approval was based on a single, multicenter,…”
Get full text

The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis by Hunter, Zachary R., Xu, Lian, Yang, Guang, Zhou, Yangsheng, Liu, Xia, Cao, Yang, Manning, Robert J., Tripsas, Christina, Patterson, Christopher J., Sheehy, Patricia, Treon, Steven P.

“…The genetic basis for Waldenström macroglobulinemia (WM) remains to be clarified. Although 6q losses are commonly present, recurring gene losses in this region…”
Get full text

Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia by ROCCARO, Aldo M, LELEU, Xavier, RUSSO, Domenico, VACCA, Angelo, DAMMACCO, Franco, ANDERSON, Kenneth C, GHOBRIAL, Irene M, TREON, Steven P, SACCO, Antonio, MOREAU, Anne-Sophie, HATJIHARISSI, Evdoxia, XIAOYING JIA, LIAN XU, CICCARELLI, Bryan, PATTERSON, Christopher J, NGO, Hait

“…Purpose: Resveratrol (3,4',5-tri-hydroxy- trans -stilbene) is an antioxidant constituent of a wide variety of plant species including grapes. It has gained…”
Get full text